[Breast Cancer: Targets and Therapy] A retrospective chart review of a cohort of patients with TNBC found that tumor size and nodal status is associated with DFS, and radiotherapy technique and fractionation protocol were not associated with differences in either DFS or OS.
[Cancer Management and Research] Gender socialisation experiences may reinforce anger and emotion suppression responses in times of distress in men with prostate cancer.
[Cancer Management and Research] Use of inflammatory indices, particularly C-reactive protein/albumin ratio (CAR), is effective in predicting risk for postoperative complications in patients undergoing resection of colorectal cancer.
[Lung Cancer: Targets and Therapy] A review of the available data on lurbinectedin, a novel RNA-polymerase-II inhibitor that has shown promise as a single agent or in combination with chemotherapy in the second-line treatment of small-cell lung cancer.
[Breast Cancer: Targets and Therapy] This study presents the findings of a review of studies in the literature on available tools for assessing the coping skills of spouses and caregivers of patients with breast cancer.
[Cancer Management and Research] A comparison of the ABCD regimen for newly diagnosed multiple myeloma with the standard BD regimen sought to determine efficacy and safety of the former regimen, as relapse or refractory disease is common with the standard BD regimen.
[Cancer Management and Research] This retrospective analysis of a cohort of 404 patients with lung cancer reports a correlation was found between sleep quality and survival among patients with lung cancer.
[Cancer Management and Research] This retrospective analysis sought to determine the predictive value of GNRI in determining postoperative complication risk and long-term prognosis in elderly patients with colorectal cancer, as well as support for nutrition interventions.
[Cancer Management and Research] A single-institution study that evaluated the efficacy and safety of apatinib, a specific TKI, in patients aged 16 years and older with advanced osteosarcoma progressing on chemotherapy showed that some AEs may be markers for improved PFS and clinical benefit rate.
[Cancer Management and Research] FDA approval of ramucirumab has improved overall survival for patients with advanced gastric carcinoma; however, most patients do not achieve a cure, heightening awareness of health-related quality of life. This report focused on HRQoL and the impact of ramucirumab on HRQoL, as well as summarized studies evaluating the benefits of systemic therapies on HRQoL in patients with advanced gastric cancer.